Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant health threat as it stems from antibiotic-resistant strains of the bacterium. This infection manifests in two primary forms: hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA). MRSA infections cover a spectrum of health issues, ranging from skin infections and bone/joint infections to bacteremia and even affecting animals. Addressing MRSA necessitates the use of antibiotics, including trimethoprim-sulfamethoxazole, clindamycin, minocycline, and doxycycline.
The conventional antibiotic Vancomycin, once a stalwart in treating MRSA, is witnessing declining clinical efficacy and efficiency. The emergence of vancomycin-resistant Staphylococcus aureus further complicates treatment. Consequently, the medical community is shifting towards newer antibiotics like Daptomycin, Clindamycin, Tigecycline, Quinupristin/dalfopristin, among others, to combat the evolving challenges of antibiotic resistance.
In response to the rise of resistant strains, there is a growing inclination towards utilizing antibiotic combinations. This strategic approach aims to reduce the likelihood and potential for the development of resistance to the newly introduced antibiotics. By employing a combination of antibiotics, medical practitioners seek to enhance the effectiveness of treatment while minimizing the risk of resistance development.
The treatment landscape for MRSA is evolving, driven by the need for innovative solutions in the face of antibiotic resistance. Daptomycin, for instance, is proving to be an effective alternative, offering a mechanism of action distinct from traditional antibiotics. Clindamycin, Tigecycline, and Quinupristin/dalfopristin are also gaining prominence as viable options to address MRSA infections, especially when faced with resistance issues.
The urgency to adapt treatment strategies arises from the continual evolution of antibiotic-resistant strains, emphasizing the importance of staying ahead in the fight against MRSA. Antibiotic combinations, featuring a mix of newer and existing antibiotics, represent a proactive approach to address the complexity of MRSA infections and minimize the risk of resistance development.
As the medical community navigates the challenges posed by MRSA, ongoing research and development are crucial for identifying novel antibiotics and optimizing treatment regimens. The ultimate goal is to ensure effective and sustainable solutions to combat MRSA infections, safeguarding public health and minimizing the impact of antibiotic resistance in clinical settings.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|
MRSA Drugs Market Highlights:
MRSA Drugs Market Overview
The MRSA Drugs Market is projected to reach USD 4130.46 Million by 2030 at 4.4% CAGR during the forecast period 2022-2030. Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen. This infection is generally associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain methicillin-resistant staphylococcus aureus infection.
The increase in the prevalence of MRSA infections and number of hospitals, growing awareness about a bacterial infection, and increase in immuno-compromised population are expected to enhance the market growth. However, the high cost of novel MRSA drugs and hospital readmissions reduction program is projected to curb the growth of the market.
Market Dynamics
MRSA drugs have been gaining significant growth in recent years owing to the rising awareness about MRSA infections. For instance, October is celebrated as world MRSA awareness month and November 18, is celebrated as antibiotic awareness day in Europe to raise awareness of antibiotic resistance and promote the judicious use of antibiotics. Thus, the growing awareness about the cause and treatment related to bacterial infection among the population led to an increased usage of MRSA drug market, which thereby provides a favorable scenario for the market to grow during the forecast period.
MRSA Drugs Market Share, by MRSA Type, 2016 & 2023 Â 
Source: MRFR Analysis
Segmentation
The MRSA drugs market, by drug class, has been segmented into sulfa drugs, tetracyclines, oxazolidinones, folate antagonists, lipopeptide, glycopeptide antibiotics, and others. Based on MRSA types, the MRSA drugs market has been categorized as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA). By disease indication, the market is divided into skin infections, bone and joint infections, and bacteremia, and animal infections. Based on end user, the MRSA Drugs market has been categorized as hospitals and clinics, research and academic institutes, and others.
North America MRSA Drugs Market Share, 2016 (%) Â 
Source: MRFR Analysis
Regional Analysis
The MRSA drugs market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to hold the largest share of the MRSA drugs market. This is owing to the presence of key market players, well-developed healthcare infrastructure, in the US and Canada. Canada held 25% in North America MRSA Drugs market in 2016.
Europe holds the second position in MRSA drugs market due to the increasing research & development in the healthcare industry, availability of funds for research, rising cases of bacterial infection, and increasing adoption of novel drugs for the treatment of MRSA.
Asia-Pacific is projected to be the fastest-growing region in the global market due to the rapidly developing medical industry, the presence of a huge patient pool, and increasing expenditure in healthcare by the government. China held a share of 25.1% in the Asia-Pacific MRSA drugs market in 2016. The Middle East & Africa holds the least market share in the MRSA drugs market.
Key Players
The prominent players in the MRSA drugs market are Merck KGaA (UK), Olon (Italy), Allergan (Dublin, Ireland), Baxter (US), Theravance Biopharma (Theravance Biopharma), Pfizer (US), Mylan NV (US), and Novartis (Switzerland).
Some of the key strategies followed by players operating in the MRSA drugs market were innovation, product development, and acquisition & mergers.
- Americas showed high demand for the high-end MRSA drugs products due to broader market size and higher spending power.
- China is expected to be one of the top three fastest-growing markets for MRSA drugs shortly.
- Merck KGaA and Pfizer PLC are some of the prominent market players in the MRSA drugs market.
Market Segmentation
MRSA Drugs Market, by Drug Class
- Sulfa Drugs
- Tetracyclines
- Oxazolidinones
- Folate Antagonists
- Lipopeptide
- Glycopeptide Antibiotics
- Others
MRSA Drugs Market, by MRSA Type
- Hospital-Acquired (HA-MRSA)
- Community-Acquired (CA-MRSA)
MRSA Drugs Market, by Disease Indication
- Skin Infections
- Bone and Joint Infections
- Bacteremia
- Animal Infections
MRSA Drugs Market, by End User
- Hospitals and Clinics
- Research and Academic Institutes
- Others
MRSA Drugs Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
-
Company Profiles of Other Key Players- The Medicines Company
- Basilea Pharmaceutica Ltd
- Cellceutix
- Cempra
- CrystalGenomics
- Debiopharm
- Galapagos
- GSK
- MRSA Drugs Market, Industry Trends
Intended Audience
- Pharmaceutical companies
-
Contract research manufacturing organizations - Research & development organizations
- Academic institutes
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
